These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33657135)

  • 61. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
    Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
    J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
    Wheatley AK; Pymm P; Esterbauer R; Dietrich MH; Lee WS; Drew D; Kelly HG; Chan LJ; Mordant FL; Black KA; Adair A; Tan HX; Juno JA; Wragg KM; Amarasena T; Lopez E; Selva KJ; Haycroft ER; Cooney JP; Venugopal H; Tan LL; O Neill MT; Allison CC; Cromer D; Davenport MP; Bowen RA; Chung AW; Pellegrini M; Liddament MT; Glukhova A; Subbarao K; Kent SJ; Tham WH
    Cell Rep; 2021 Oct; 37(2):109822. PubMed ID: 34610292
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Structure basis of two nanobodies neutralizing SARS-CoV-2 Omicron variant by targeting ultra-conservative epitopes.
    Sun Z; Wang L; Li L; Sun Y; Zhang D; Zhou S; Li Y; Li X; Qiao H; Cui Q; Lan Z; Meng X; Xu J; Geng Y; Dai Y
    J Struct Biol; 2023 Sep; 215(3):107996. PubMed ID: 37419228
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
    Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
    Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate.
    Jung BK; An YH; Jang JJ; Jeon JH; Jang SH; Jang H
    PLoS One; 2022; 17(2):e0263684. PubMed ID: 35134091
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.
    Zou J; Li L; Zheng P; Liang W; Hu S; Zhou S; Wang Y; Zhao J; Yuan D; Liu L; Wu D; Xu M; Zhang F; Zhu M; Wu Z; Cao X; Ni M; Ling X; Wu Y; Kuang Z; Hu M; Li J; Li X; Guo X; Xu T; Jiang H; Gao C; Yu M; Liu J; Zhong N; Zhou J; Huang JA; Jin T; He J
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35108220
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prospects of Neutralizing Nanobodies Against SARS-CoV-2.
    Chen F; Liu Z; Jiang F
    Front Immunol; 2021; 12():690742. PubMed ID: 34122456
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein.
    Jiang X; Qin Q; Zhu H; Qian J; Huang Q
    Int J Biol Macromol; 2024 Jan; 256(Pt 1):128191. PubMed ID: 38000614
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Identification of a potent SARS-CoV-2 neutralizing nanobody targeting the receptor-binding domain of the spike protein.
    Liu C; Hadiatullah H; Yuchi Z
    Int J Biol Macromol; 2024 Nov; 281(Pt 2):136403. PubMed ID: 39383917
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Screening and affinity optimization of single domain antibody targeting the SARS-CoV-2 nucleocapsid protein.
    Yang Q; Yan M; Lin J; Lu Y; Lin S; Li Z; Wang H; Yang J; Zhang N; Chen X
    PeerJ; 2024; 12():e17846. PubMed ID: 39224822
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain.
    Rossotti MA; González-Techera A; Guarnaschelli J; Yim L; Camacho X; Fernández M; Cabral P; Leizagoyen C; Chabalgoity JA; González-Sapienza G
    MAbs; 2015; 7(5):820-8. PubMed ID: 26192995
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Plant virus-derived nanoparticles decorated with genetically encoded SARS-CoV-2 nanobodies display enhanced neutralizing activity.
    Merwaiss F; Lozano-Sanchez E; Zulaica J; Rusu L; Vazquez-Vilar M; Orzáez D; Rodrigo G; Geller R; Daròs JA
    Plant Biotechnol J; 2024 Apr; 22(4):876-891. PubMed ID: 37966715
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time.
    Czajka TF; Vance DJ; Mantis NJ
    Trends Microbiol; 2021 Mar; 29(3):195-203. PubMed ID: 33446406
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape.
    Starr TN; Czudnochowski N; Zatta F; Park YJ; Liu Z; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Tucker H; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Cameroni E; Croll TI; Nix JC; Havenar-Daughton C; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Whelan SPJ; Virgin HW; Veesler D; Corti D; Bloom JD; Snell G
    bioRxiv; 2021 Apr; ():. PubMed ID: 33851154
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Llamanade: An open-source computational pipeline for robust nanobody humanization.
    Sang Z; Xiang Y; Bahar I; Shi Y
    Structure; 2022 Mar; 30(3):418-429.e3. PubMed ID: 34895471
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of an Affinity-Enhanced Anti-SARS-CoV2 Nanobody Design Workflow Using Machine Learning and Molecular Dynamics.
    Fazekas Z; Nagy-Fazekas D; Shilling-Tóth BM; Ecsédi P; Stráner P; Nyitray L; Perczel A
    J Chem Inf Model; 2024 Oct; 64(19):7626-7638. PubMed ID: 39356775
    [No Abstract]   [Full Text] [Related]  

  • 78. Unsupervised evolution of protein and antibody complexes with a structure-informed language model.
    Shanker VR; Bruun TUJ; Hie BL; Kim PS
    Science; 2024 Jul; 385(6704):46-53. PubMed ID: 38963838
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Designed proteins assemble antibodies into modular nanocages.
    Divine R; Dang HV; Ueda G; Fallas JA; Vulovic I; Sheffler W; Saini S; Zhao YT; Raj IX; Morawski PA; Jennewein MF; Homad LJ; Wan YH; Tooley MR; Seeger F; Etemadi A; Fahning ML; Lazarovits J; Roederer A; Walls AC; Stewart L; Mazloomi M; King NP; Campbell DJ; McGuire AT; Stamatatos L; Ruohola-Baker H; Mathieu J; Veesler D; Baker D
    Science; 2021 Apr; 372(6537):. PubMed ID: 33795432
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Contribution of an unusual CDR2 element of a single domain antibody in ricin toxin binding affinity and neutralizing activity.
    Rudolph MJ; Vance DJ; Kelow S; Angalakurthi SK; Nguyen S; Davis SA; Rong Y; Middaugh CR; Weis DD; Dunbrack R; Karanicolas J; Mantis NJ
    Protein Eng Des Sel; 2018 Jul; 31(7-8):277-287. PubMed ID: 30265352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.